Klotho as a potential biomarker and therapy for acute kidney injury

• Published in: Nature reviews. Nephrology Vol. 8; no. 7; pp. 423 - 429
• Main Authors: Hu, Ming-Chang, Moe, Orson W.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.07.2012; Nature Publishing Group
• Subjects: 692/53; 692/699/1585/4; 692/700/565/1436/2185; Acute Kidney Injury - drug therapy; Acute Kidney Injury - metabolism; Acute Kidney Injury - pathology; Animals; Apoptosis - drug effects; Apoptosis - physiology; Biomarkers; Biomarkers - metabolism; Care and treatment; Chronic kidney failure; Diagnosis; Disease Models, Animal; Fibroblast growth factors; Fibroblasts; Fibrosis - drug therapy; Fibrosis - metabolism; Glucuronidase - metabolism; Glucuronidase - therapeutic use; Growth factors; Humans; Ischemia; Kidney - metabolism; Kidney diseases; Kidney Failure, Chronic - prevention & control; Medicine; Medicine & Public Health; Membrane proteins; Metabolism; Nephrology; opinion-2; Physiological aspects; Proteins; Reperfusion Injury - drug therapy; Reperfusion Injury - metabolism; Reperfusion Injury - pathology; Rodentia; United States

Klotho deficiency is now considered an early event in acute kidney injury (AKI), and a pathogenic factor that contributes to kidney damage. Here, the authors discuss why this renal-derived protein is a highly promising candidate as both an early biomarker and therapeutic agent for AKI. Klotho is a s...